Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 6, 2016, Pages 1352-1356

  Buchanan, Tommy R ^a   Graybill, Whitney S ^a   Pierce, Jennifer Young ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

disease reduction; human paillomavirus vaccination; vaginal cancer; vulvar cancer

Indexed keywords

WART VIRUS VACCINE;

CANCER MORTALITY; CANCER SURGERY; CHEMORADIOTHERAPY; DYSPLASIA; GENOTYPE; HUMAN; IMMUNE RESPONSE; META ANALYSIS (TOPIC); MORBIDITY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SEXUAL FUNCTION; VACCINATION; VAGINA CANCER; VIRUS GENOME; VULVA CANCER; WART VIRUS; FEMALE; IMMUNOLOGY; MORTALITY; TREATMENT OUTCOME; UTILIZATION; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

FEMALE; HUMANS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; VACCINATION; VAGINAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 84964047298     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1147634     Document Type: Review

References (42)

1. J.Berek. Berek & Hacker's gynecologic oncology (5th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health 2010
2. National Cancer Institute. SEER Stat Facts: Vulvar Cancer. Available at: http://seer.cancer.gov/statfacts/html/vulva.html; 2014. [Retrieved 2015]
3. P.Judson, E.Habermann, N.Baxter, S.Durham, B.Virnig. Trends in the Incidence of Invasive and In Situ Vulvar Carcinoma. Obstetr Gynecol 2008; 107:1018-1022
4. N.Akhtar-Danesh, L.Elit, A.Lytwyn. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: A population-based study. Gynecologic Oncol 2014; 134:314-318; PMID:24875124; http://dx.doi.org/10.1016/j.ygyno.2014.05.014
5. S.Zweizig, S.Korets, J.Cain. Key concepts in management of vulvar cancer. Best Practice Res Clin Obstet Gynaecol 2014; 28:959-966; PMID:25151473; http://dx.doi.org/10.1016/j.bpobgyn.2014.07.001
6. I.Alkatout, V.Günther, M.Schubert, M.Weigel, N.Garbrecht, W.Jonat, C.Mundhenke. Vulvar cancer: Epidemiology, clinical presentation, and management options. Int J Women's Health IJWH 2015; 7:305-305; http://dx.doi.org/10.2147/IJWH.S68979
7. H.Vuyst, G.Clifford, M.Nascimento, M.Madeleine, S.Franceschi. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int J Cancer 2009; 124:1626-1636; http://dx.doi.org/10.1002/ijc.24116
8. L.Conley, T.Ellerbrock, T.Bush, M.Chiasson, D.Sawo, T.Wright. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: A prospective cohort study. Lancet 2002; 359:108-113; http://dx.doi.org/10.1016/S0140-6736(02)07368-3
9. L.Massad. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus*1. Am J Obstetr Gynecol 2004; 190:1241-1248; PMID:15167825; http://dx.doi.org/10.1016/j.ajog.2003.12.037
10. M.Frisch. Human Papillomavirus-Associated Cancers in Patients with Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. J Natl Cancer Inst 2000; 92:1500-1510; PMID:10995805; http://dx.doi.org/10.1093/jnci/92.18.1500
11. J.Rauh-Hain, J.Clemmer, R.Clark, L.Bradford, W.Growdon, A.Goodman, M.Carmen. Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time. Am J Obstetr Gynecol 2013; 209:468.e1-468.e10; PMID:23891626
12. Y.Fu, J.Reagan. Pathology of the uterine cervix, vagina, and vulva. Philadelphia: Saunders 2002
13. R.Siegel, D.Naishadham, A.Jemal. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087
14. Key Statistics About Vaginal Cancer. Available at http://www.cancer.org/cancer/vaginalcancer/detailedguide/vaginal-cancer-key-statistics. [Retrieved 2015] 2014
15. Vaginal and Vulvar Cancers Statistics. Available at http://www.cdc.gov/cancer/vagvulv/statistics. [Retrieved 2015] 2014
16. L.Massad. Outcomes After Diagnosis of Vaginal Intraepithelial Neoplasia. J Lower Genital Tract Dis 2008; 12:16-19; PMID:18162807; http://dx.doi.org/10.1097/LGT.0b013e318074f968
17. C.Gunderson, E.Nugent, S.Elfrink, M.Gold, K.Moore. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstetr Gynecol 2013; 208:410.e1-410.e6; PMID:23380265
18. M.Hoffman, S.Decesare, W.Roberts, J.Fiorica, M.Finan, D.Cavanagh. Upper vaginectomy for in situ and occult, superficially invasive carcinoma of the vagina. Am J Obstetr Gynecol 1992; 166:30-33; PMID:1733213; http://dx.doi.org/10.1016/0002-9378(92)91823-S
19. HPV Vaccination. (2010). Available at http://www.cdc.gov/vaccines/vpd-vac/hpv/ [Retrieved 2015]
20. HPV (Human Papillomavirus) Cervarix®® VIS. (2013, June 18). Available at http://www.cdc.gov/vaccines/hcp/vis/vis-statements/hpv-Cervarix®.html. [Retrieved 2015]
21. W.Atkinson. Human Papillomavirus. In Epidemiology & prevention of vaccine-preventable diseases (13th ed.) 2015
22. R.Kirnbauer,, F.Booy,, N.Cheng,, D.Lowy,, J.Schiller. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci 1992:12180-12184
23. K.Ault. Long-term efficacy of human papillomavirus vaccination. Gynecologic Oncol. 2007; 107:S27-S30; PMID:17938016; http://dx.doi.org/10.1016/j.ygyno.2007.07.078
24. P.Naud, C.Roteli-Martins, N.Carvalho, J.Teixeira, P.Borba, N.Sanchez, D.Descamps. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccines Immunotherapeutics. 2014; 10:2147-2162; PMID:25424918; http://dx.doi.org/10.4161/hv.29532
25. M.Rahman, T.Laz, C.Mcgrath, A.Berenson. Correlates of human papillomavirus vaccine series completion among young adult female initiators. Hum Vacc Immunotherapeutics. 2014; 10:2163-2167; PMID:25424919; http://dx.doi.org/10.4161/hv.29633
26. M.Hendry, R.Lewis, A.Clements, S.Damery, C.Wilkinson. “HPV? Never heard of it!:” A systematic review of girls' and parents' information needs, views and preferences about human papillomavirus vaccination. Vaccine 2013; 31(45):5152-5167; PMID:24029117; http://dx.doi.org/10.1016/j.vaccine.2013.08.091
27. M.Gillison, A.Chaturvedi, D.Lowy. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113:3036-3046; PMID:18980286; http://dx.doi.org/10.1002/cncr.23764
28. S.Garland, M.Steben, H.Sings, M.James, S.Lu, R.Railkar, E.Joura. Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine. J Infect Dis 2009; 199:805-814; PMID:19199546; http://dx.doi.org/10.1086/597071
29. B.Serrano, L.Alemany, S.Tous, L.Bruni, G.Clifford, T.Weiss, S.Sanjosé. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infectious Agents and Cancer Infect Agents Cancer 2012; 7:38-38; PMID:23273245; http://dx.doi.org/10.1186/1750-9378-7-38
30. S.Sanjosé, L.Alemany, J.Ordi, S.Tous, M.Alejo, S.Bigby, X.Bosch. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer 2013; 49:3450-3461; http://dx.doi.org/10.1016/j.ejca.2013.06.033
31. L.Alemany, M.Saunier, L.Tinoco, B.Quirós, I.Alvarado-Cabrero, M.Alejo, X.Bosch. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014; 50:2846-2854; PMID:25155250; http://dx.doi.org/10.1016/j.ejca.2014.07.018
32. N.Garçon, M.Wettendorff, M.Mechelen. Role of AS04 in human papillomavirus vaccine: Mode of action and clinical profile. Expert Opin Biol Ther Expert Opinion Biological Therapy 2011; 11:667-677; http://dx.doi.org/10.1517/14712598.2011.573624
33. J.Paavonen, P.Naud, J.Salmerón, C.Wheeler, S.Chow, D.Apter, G.Dubin. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-314; PMID:19586656
34. FUTURE II Study Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Eng J Med 2007; 356:1915-1927; PMID:17494925
35. S.Garland, M.Hernandez-Avila, C.Wheeler, G.Perez, D.Harper, S.Leodolter, L.Koutsky. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med 2007; 356:1928-1943; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760
36. N.S.K.Munoz, K.Kjaer, O.E.Sigurdsson, M.Iversen, C.M.Hernandez-Avila, G.Wheeler. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009; 199:936-944; PMID:19236277
37. S.Tabrizi, J.Brotherton, J.Kaldor, S.Skinner, E.Cummins, B.Liu, S.Garland. Fall in Human Papillomavirus Prevalence Following a National Vaccination Program. J Infect Dis. 2012; 206:1645-1651; PMID:23087430; http://dx.doi.org/10.1093/infdis/jis590
38. H.Ali, B.Donovan, H.Wand, T.Read, D.Regan, A.Grulich, R.Guy. Genital warts in young Australians five years into national human papillomavirus vaccination programme: National surveillance data. Bmj 2013; 346:f2032
39. Teen Vaccination Coverage. (2015, July 30). Retrieved 2015, from http://www.cdc.gov/vaccines/who/teens/vaccination-coverage.html
40. Broader disease coverage due to more HPV types. 2015. Retrieved 2015, from https://www.merckvaccines.com/Products/Gardasil9/Pages/why9
41. E.Herweijer, A.Leval, A.Ploner, S.Eloranta, J.Simard, J.Dillner, L.Arnheim-Dahlström. Association of Varying Number of Doses of Quadrivalent Human Papillomavirus Vaccine With Incidence of Condyloma. JAMA 2014; 311:597-603; PMID:24519299; http://dx.doi.org/10.1001/jama.2014.95
42. National Cancer Institute. Vaginal Cancer treatment. Available at: http://cancer.gov/types/hp/vaginal-treatment; 2015. [Retrieved 2015]